Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.
Identifieur interne : 000182 ( PubMed/Curation ); précédent : 000181; suivant : 000183Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.
Auteurs : Carine Chassain [France] ; Christophe Melon [France] ; Pascal Salin [France] ; Flora Vitale [France] ; Sébastien Couraud [France] ; Franck Durif [France] ; Lydia Kerkerian-Le Goff [France] ; Paolo Gubellini [France]Source :
- Journal of neurochemistry [ 1471-4159 ] ; 2016.
English descriptors
- KwdEn :
- Animals, Basal Ganglia (metabolism), Basal Ganglia (physiopathology), Behavior, Animal (drug effects), Corpus Striatum (metabolism), Corpus Striatum (physiopathology), Deep Brain Stimulation (methods), Dopamine (metabolism), Glutamic Acid (metabolism), Neuronal Plasticity (drug effects), Oxidopamine (pharmacology), Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Parkinson Disease (therapy), Rats, Substantia Nigra (metabolism), Substantia Nigra (physiopathology), Subthalamic Nucleus (metabolism), Subthalamic Nucleus (physiopathology), Time.
- MESH :
- chemical , metabolism : Dopamine, Glutamic Acid.
- drug effects : Behavior, Animal, Neuronal Plasticity.
- metabolism : Basal Ganglia, Corpus Striatum, Parkinson Disease, Substantia Nigra, Subthalamic Nucleus.
- methods : Deep Brain Stimulation.
- chemical , pharmacology : Oxidopamine.
- physiopathology : Basal Ganglia, Corpus Striatum, Parkinson Disease, Substantia Nigra, Subthalamic Nucleus.
- therapy : Parkinson Disease.
- Animals, Rats, Time.
Abstract
The long-term effects and action mechanisms of subthalamic nucleus (STN) high-frequency stimulation (HFS) for Parkinson's disease still remain poorly characterized, mainly due to the lack of experimental models relevant to clinical application. To address this issue, we performed a multilevel study in freely moving hemiparkinsonian rats undergoing 5-week chronic STN HFS, using a portable constant-current microstimulator. In vivo metabolic neuroimaging by (1) H-magnetic resonance spectroscopy (11.7 T) showed that STN HFS normalized the tissue levels of the neurotransmission-related metabolites glutamate, glutamine and GABA in both the striatum and substantia nigra reticulata (SNr), which were significantly increased in hemiparkinsonian rats, but further decreased nigral GABA levels below control values; taurine levels, which were not affected in hemiparkinsonian rats, were significantly reduced. Slice electrophysiological recordings revealed that STN HFS was, uniquely among antiparkinsonian treatments, able to restore both forms of corticostriatal synaptic plasticity, i.e. long-term depression and potentiation, which were impaired in hemiparkinsonian rats. Behavior analysis (staircase test) showed a progressive recovery of motor skill during the stimulation period. Altogether, these data show that chronic STN HFS efficiently counteracts metabolic and synaptic defects due to dopaminergic lesion in both the striatum and SNr. Comparison of chronic STN HFS with acute and subchronic treatment further suggests that the long-term benefits of this treatment rely both on the maintenance of acute effects and on delayed actions on the basal ganglia network. We studied the effects of chronic (5 weeks) continuous subthalamic nucleus (STN) high-frequency stimulation (HFS) in hemiparkinsonian rats. The levels of glutamate and GABA in the striatum () and substantia nigra reticulata (SNr) (), measured by in vivo proton magnetic resonance spectroscopy ((1) H-MRS), were increased by 6-hydroxydopamine (6-OHDA) lesion, which also disrupted corticostriatal synaptic plasticity () and impaired forepaw skill () in the staircase test. Five-week STN HFS normalized glutamate and GABA levels and restored both synaptic plasticity and motor function. A partial behavioral recovery was observed at 2-week STN HFS.
DOI: 10.1111/jnc.13438
PubMed: 26576509
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000182
Links to Exploration step
pubmed:26576509Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.</title>
<author><name sortKey="Chassain, Carine" sort="Chassain, Carine" uniqKey="Chassain C" first="Carine" last="Chassain">Carine Chassain</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier Universitaire (CHU) Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Hospitalier Universitaire (CHU) Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Melon, Christophe" sort="Melon, Christophe" uniqKey="Melon C" first="Christophe" last="Melon">Christophe Melon</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Salin, Pascal" sort="Salin, Pascal" uniqKey="Salin P" first="Pascal" last="Salin">Pascal Salin</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vitale, Flora" sort="Vitale, Flora" uniqKey="Vitale F" first="Flora" last="Vitale">Flora Vitale</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Couraud, Sebastien" sort="Couraud, Sebastien" uniqKey="Couraud S" first="Sébastien" last="Couraud">Sébastien Couraud</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier Universitaire (CHU) Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Hospitalier Universitaire (CHU) Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kerkerian Le Goff, Lydia" sort="Kerkerian Le Goff, Lydia" uniqKey="Kerkerian Le Goff L" first="Lydia" last="Kerkerian-Le Goff">Lydia Kerkerian-Le Goff</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gubellini, Paolo" sort="Gubellini, Paolo" uniqKey="Gubellini P" first="Paolo" last="Gubellini">Paolo Gubellini</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26576509</idno>
<idno type="pmid">26576509</idno>
<idno type="doi">10.1111/jnc.13438</idno>
<idno type="wicri:Area/PubMed/Corpus">000182</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000182</idno>
<idno type="wicri:Area/PubMed/Curation">000182</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000182</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.</title>
<author><name sortKey="Chassain, Carine" sort="Chassain, Carine" uniqKey="Chassain C" first="Carine" last="Chassain">Carine Chassain</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier Universitaire (CHU) Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Hospitalier Universitaire (CHU) Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Melon, Christophe" sort="Melon, Christophe" uniqKey="Melon C" first="Christophe" last="Melon">Christophe Melon</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Salin, Pascal" sort="Salin, Pascal" uniqKey="Salin P" first="Pascal" last="Salin">Pascal Salin</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vitale, Flora" sort="Vitale, Flora" uniqKey="Vitale F" first="Flora" last="Vitale">Flora Vitale</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Couraud, Sebastien" sort="Couraud, Sebastien" uniqKey="Couraud S" first="Sébastien" last="Couraud">Sébastien Couraud</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier Universitaire (CHU) Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Hospitalier Universitaire (CHU) Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kerkerian Le Goff, Lydia" sort="Kerkerian Le Goff, Lydia" uniqKey="Kerkerian Le Goff L" first="Lydia" last="Kerkerian-Le Goff">Lydia Kerkerian-Le Goff</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gubellini, Paolo" sort="Gubellini, Paolo" uniqKey="Gubellini P" first="Paolo" last="Gubellini">Paolo Gubellini</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of neurochemistry</title>
<idno type="eISSN">1471-4159</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Basal Ganglia (metabolism)</term>
<term>Basal Ganglia (physiopathology)</term>
<term>Behavior, Animal (drug effects)</term>
<term>Corpus Striatum (metabolism)</term>
<term>Corpus Striatum (physiopathology)</term>
<term>Deep Brain Stimulation (methods)</term>
<term>Dopamine (metabolism)</term>
<term>Glutamic Acid (metabolism)</term>
<term>Neuronal Plasticity (drug effects)</term>
<term>Oxidopamine (pharmacology)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (therapy)</term>
<term>Rats</term>
<term>Substantia Nigra (metabolism)</term>
<term>Substantia Nigra (physiopathology)</term>
<term>Subthalamic Nucleus (metabolism)</term>
<term>Subthalamic Nucleus (physiopathology)</term>
<term>Time</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
<term>Glutamic Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term>
<term>Neuronal Plasticity</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term>
<term>Corpus Striatum</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Deep Brain Stimulation</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Oxidopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Basal Ganglia</term>
<term>Corpus Striatum</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Rats</term>
<term>Time</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The long-term effects and action mechanisms of subthalamic nucleus (STN) high-frequency stimulation (HFS) for Parkinson's disease still remain poorly characterized, mainly due to the lack of experimental models relevant to clinical application. To address this issue, we performed a multilevel study in freely moving hemiparkinsonian rats undergoing 5-week chronic STN HFS, using a portable constant-current microstimulator. In vivo metabolic neuroimaging by (1) H-magnetic resonance spectroscopy (11.7 T) showed that STN HFS normalized the tissue levels of the neurotransmission-related metabolites glutamate, glutamine and GABA in both the striatum and substantia nigra reticulata (SNr), which were significantly increased in hemiparkinsonian rats, but further decreased nigral GABA levels below control values; taurine levels, which were not affected in hemiparkinsonian rats, were significantly reduced. Slice electrophysiological recordings revealed that STN HFS was, uniquely among antiparkinsonian treatments, able to restore both forms of corticostriatal synaptic plasticity, i.e. long-term depression and potentiation, which were impaired in hemiparkinsonian rats. Behavior analysis (staircase test) showed a progressive recovery of motor skill during the stimulation period. Altogether, these data show that chronic STN HFS efficiently counteracts metabolic and synaptic defects due to dopaminergic lesion in both the striatum and SNr. Comparison of chronic STN HFS with acute and subchronic treatment further suggests that the long-term benefits of this treatment rely both on the maintenance of acute effects and on delayed actions on the basal ganglia network. We studied the effects of chronic (5 weeks) continuous subthalamic nucleus (STN) high-frequency stimulation (HFS) in hemiparkinsonian rats. The levels of glutamate and GABA in the striatum () and substantia nigra reticulata (SNr) (), measured by in vivo proton magnetic resonance spectroscopy ((1) H-MRS), were increased by 6-hydroxydopamine (6-OHDA) lesion, which also disrupted corticostriatal synaptic plasticity () and impaired forepaw skill () in the staircase test. Five-week STN HFS normalized glutamate and GABA levels and restored both synaptic plasticity and motor function. A partial behavioral recovery was observed at 2-week STN HFS.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26576509</PMID>
<DateCreated><Year>2016</Year>
<Month>02</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>08</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>02</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-4159</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>136</Volume>
<Issue>5</Issue>
<PubDate><Year>2016</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Journal of neurochemistry</Title>
<ISOAbbreviation>J. Neurochem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.</ArticleTitle>
<Pagination><MedlinePgn>1004-16</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/jnc.13438</ELocationID>
<Abstract><AbstractText>The long-term effects and action mechanisms of subthalamic nucleus (STN) high-frequency stimulation (HFS) for Parkinson's disease still remain poorly characterized, mainly due to the lack of experimental models relevant to clinical application. To address this issue, we performed a multilevel study in freely moving hemiparkinsonian rats undergoing 5-week chronic STN HFS, using a portable constant-current microstimulator. In vivo metabolic neuroimaging by (1) H-magnetic resonance spectroscopy (11.7 T) showed that STN HFS normalized the tissue levels of the neurotransmission-related metabolites glutamate, glutamine and GABA in both the striatum and substantia nigra reticulata (SNr), which were significantly increased in hemiparkinsonian rats, but further decreased nigral GABA levels below control values; taurine levels, which were not affected in hemiparkinsonian rats, were significantly reduced. Slice electrophysiological recordings revealed that STN HFS was, uniquely among antiparkinsonian treatments, able to restore both forms of corticostriatal synaptic plasticity, i.e. long-term depression and potentiation, which were impaired in hemiparkinsonian rats. Behavior analysis (staircase test) showed a progressive recovery of motor skill during the stimulation period. Altogether, these data show that chronic STN HFS efficiently counteracts metabolic and synaptic defects due to dopaminergic lesion in both the striatum and SNr. Comparison of chronic STN HFS with acute and subchronic treatment further suggests that the long-term benefits of this treatment rely both on the maintenance of acute effects and on delayed actions on the basal ganglia network. We studied the effects of chronic (5 weeks) continuous subthalamic nucleus (STN) high-frequency stimulation (HFS) in hemiparkinsonian rats. The levels of glutamate and GABA in the striatum () and substantia nigra reticulata (SNr) (), measured by in vivo proton magnetic resonance spectroscopy ((1) H-MRS), were increased by 6-hydroxydopamine (6-OHDA) lesion, which also disrupted corticostriatal synaptic plasticity () and impaired forepaw skill () in the staircase test. Five-week STN HFS normalized glutamate and GABA levels and restored both synaptic plasticity and motor function. A partial behavioral recovery was observed at 2-week STN HFS.</AbstractText>
<CopyrightInformation>© 2015 International Society for Neurochemistry.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chassain</LastName>
<ForeName>Carine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Centre Hospitalier Universitaire (CHU) Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Melon</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Salin</LastName>
<ForeName>Pascal</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vitale</LastName>
<ForeName>Flora</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Couraud</LastName>
<ForeName>Sébastien</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Durif</LastName>
<ForeName>Franck</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Centre Hospitalier Universitaire (CHU) Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kerkerian-Le Goff</LastName>
<ForeName>Lydia</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gubellini</LastName>
<ForeName>Paolo</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Institut de Biologie du Développement de Marseille (IBDM) UMR7288, Aix-Marseille Université, CNRS, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>12</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Neurochem</MedlineTA>
<NlmUniqueID>2985190R</NlmUniqueID>
<ISSNLinking>0022-3042</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber>
<NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber>
<NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D046690" MajorTopicYN="Y">Deep Brain Stimulation</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013995" MajorTopicYN="N">Time</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">high-frequency stimulation</Keyword>
<Keyword MajorTopicYN="N">nuclear magnetic resonance</Keyword>
<Keyword MajorTopicYN="N">striatum</Keyword>
<Keyword MajorTopicYN="N">substantia nigra</Keyword>
<Keyword MajorTopicYN="N">subthalamic nucleus</Keyword>
<Keyword MajorTopicYN="N">synaptic plasticity</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>08</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>10</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>11</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>8</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26576509</ArticleId>
<ArticleId IdType="doi">10.1111/jnc.13438</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000182 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000182 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:26576509 |texte= Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26576509" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |